Immune Checkpoint Blockade Combined with AbnobaViscum(®) Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence.
- DOI
- 10.3390/ph17121713
- Published
- 2024 Dec 18
- Container
- Pharmaceuticals (Basel, Switzerland)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/ph17121713,
title = {Immune Checkpoint Blockade Combined with AbnobaViscum(®) Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence.},
author = {Schad F and Thronicke A and Hofheinz RD and Klein R and Grabowski P and Oei SL and Wüstefeld H and Grah C},
year = {2024},
journal = {Pharmaceuticals (Basel, Switzerland)},
doi = {10.3390/ph17121713},
url = {https://doi.org/10.3390/ph17121713}
}RIS
TY - JOUR TI - Immune Checkpoint Blockade Combined with AbnobaViscum(®) Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence. AU - Schad F AU - Thronicke A AU - Hofheinz RD AU - Klein R AU - Grabowski P AU - Oei SL AU - Wüstefeld H AU - Grah C PY - 2024 JO - Pharmaceuticals (Basel, Switzerland) DO - 10.3390/ph17121713 UR - https://doi.org/10.3390/ph17121713 ER -
APA
F, S., A, T., RD, H., R, K., P, G., SL, O., H, W., & C, G. (2024). Immune Checkpoint Blockade Combined with AbnobaViscum(®) Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-Small-Cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-World Evidence.. Pharmaceuticals (Basel, Switzerland). https://doi.org/10.3390/ph17121713
Source records
- pubmed · retrieved 2026-09-26T19:54:19.265Z